Phase 2 Study of Vinblastine in Children With Recurrent or Refractory Low Grade Glioma
Launched by THE HOSPITAL FOR SICK CHILDREN · Sep 13, 2005
Trial Information
Current as of June 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \< 21 years of age at original diagnosis
- • histological verification of low grade glioma (glial tumors, neuronal tumors or chiasmatic-hypothalamic tumor) at original diagnosis
- • evidence of tumor recurrence or progression by MRI or contrast CT
- • Karnofsky and Lansky performance status of 0,1 or 2
- • life expectancy of greater than or equal to 2 months
- • adequate organ and bone marrow function within 7 days of starting treatment with Vinblastine
- • absolute neutrophil count (ANC)\> 1000/uL
- • platelet count \> 100,000/uL (transfusion independent)
- • serum creatinine \< 1.5 x normal for age
- • written informed consent signed by subject and/or subject's parent/legal guardian
- Exclusion Criteria:
- • not recovered from the acute toxic effects of all prior chemotherapy, immunotherapy or radiotherapy
- • chemotherapy within 2 weeks of entry in study (4 weeks if prior nitrosourea was used)
- • less than 7 days since the completion of therapy with a biologic agent
- • less than 2 months since cranial/spinal radiation
- • receiving a stable dose of dexamethasone for less than one week
About The Hospital For Sick Children
The Hospital for Sick Children (SickKids) is a leading pediatric health care and research institution located in Toronto, Canada. With a commitment to advancing child health through innovative research, education, and clinical care, SickKids is recognized globally for its expertise in pediatric medicine. The hospital actively sponsors clinical trials aimed at improving treatment outcomes and enhancing the quality of life for children with various health conditions. By fostering collaboration among multidisciplinary teams and leveraging state-of-the-art facilities, SickKids strives to translate research findings into tangible advancements in pediatric care, ensuring that children receive the best possible treatments based on the latest scientific evidence.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Eric Bouffet, MD
Principal Investigator
The Hospital for Sick Children, Toronto Canada
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials